The World Health Organization (WHO) has reported a significant drop in global mpox (formerly known as monkeypox) cases, attributing the progress largely to expanded vaccine access and improved disease surveillance efforts. In its 55th situation update, published today, the agency noted that regions with higher vaccination rates, particularly in Central and West Africa, have seen a sharp reduction in new infections and transmission clusters.

Mpox, a viral disease that previously saw a spike in global cases in 2022 and 2023, had caused major concern among health authorities due to its rapid spread, especially in urban and interconnected regions. However, the availability of the JYNNEOS and LC16 vaccines through international partnerships and donation efforts has helped countries roll out targeted immunization programs.

According to the WHO, countries with early detection systems and at-risk group vaccination strategies—such as frontline health workers, laboratory staff, and exposed communities—have been more successful in containing the virus. In areas like Nigeria and the Democratic Republic of Congo, where mpox had previously overwhelmed public health systems, the virus is now more effectively contained, with fewer hospitalizations and localized outbreaks.

However, WHO experts caution that the global vaccination coverage still lags in several rural regions, where logistical barriers and vaccine hesitancy remain challenges. They urge governments and global health partners to continue funding awareness campaigns, invest in mobile clinics, and sustain vaccination efforts through the year.

“Mpox is no longer a global emergency, but complacency would reverse the gains we’ve made,” stated Dr. Rosamund Lewis, WHO’s technical lead on mpox. She emphasized the need for equity in vaccine distribution to prevent resurgence.